http://rdf.ncbi.nlm.nih.gov/pubchem/patent/AR-116109-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_cf32b60391b469c41e86c353437f5751 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4545 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-454 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D401-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-498 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D401-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D401-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D401-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-454 |
| filingDate | 2019-07-05-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2021-03-31-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | AR-116109-A1 |
| titleOfInvention | DERIVATIVES OF 3- (5-AMINO-1-OXOISOINDOLIN-2-IL) PIPERIDINE-2,6-DIONA AND USES OF THE SAME |
| abstract | The present disclosure provides a compound of formula (1), or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer or tautomer thereof, wherein Rᵃ, Rᵇ, Rˣ, R¹, R², X² and q are as defined in present, and methods of preparation and use thereof. Claim 1: A compound of formula (1), wherein: X¹ and X² are each independently H, C₁₋₄ alkyl, C₁₋₆ alkoxy, C₁₋₄ haloalkyl, C₁₋₆ haloalkoxy, C₃₋₇ cycloalkyl, halogen, CN, -OH or -NH₂; Rˣ is H or D; each Rᵃ and Rᵇ is independently H or D, or Rᵃ and Rᵇ together with the atom to which they are attached form =(O); R¹ is a compound selected from the group of formulas (2); R² is H, C₁₋₆ alkyl, C₁₋₆ haloalkyl or C₃₋₆ cycloalkyl; or R² and R⁷ together with the nitrogen atoms to which they are attached form a 6- or 7-membered heterocycloalkyl ring; each R³ is independently at each occurrence C₁₋₆ alkyl, C₁₋₆ alkoxy, C₁₋₆ haloalkyl, C₁₋₆ haloalkoxy, halogen, CN, -OH, or -NH₂; or two R³ together with the carbon atoms to which they are attached form a C₃₋₇ cycloalkyl or a 4 to 7 membered heterocycloalkyl ring comprising 1-3 heteroatoms selected from O, N and S; or two R³ together when on adjacent carbon atoms form a phenyl or 5- or 6-membered heteroaryl ring comprising 1-3 heteroatoms selected from O, N and S; or R³ and R⁷ together with the nitrogen and carbon atoms to which they are attached form a 5- or 6-membered heterocycloalkyl ring optionally comprising 1 to 2 additional heteroatoms selected from O, N and S, optionally substituted with 1 to 4 substituents each one independently selected from C₁₋₆ alkyl, C₁₋₆ haloalkyl, halogen, -OH, CN, and -NH₂; each R⁴ is C₁₋₆ alkyl, C₁₋₆ alkoxy, C₁₋₆ haloalkyl, C₁₋₆ haloalkoxy, halogen, -OH, or -NH₂; R⁵ is -OR⁶ or -NR⁷R⁷; R⁶ is H, C₁₋₆ alkyl, C₁₋₆ haloalkyl, -C(O)C₁₋₆ alkyl, C₃₋₇ cycloalkyl, 5- or 6-membered heterocycloalkyl comprising 1-3 heteroatoms selected from O, N and S, aryl C₆₋₁₀, or 5- or 6-membered heteroaryl comprising 1-3 heteroatoms selected from O, N, and S, wherein alkyl is optionally substituted with 1 to 3 substituents each independently selected from C₆₋₁₀-aryl and 5-membered heteroaryl or 6 membered comprising 1-3 heteroatoms selected from O, N and S; R⁷ and R⁷ are each independently H, C₁₋₆ alkyl, C₁₋₆ haloalkyl, C₃₋₇ cycloalkyl, 5- or 6-membered heterocycloalkyl comprising 1-3 heteroatoms selected from O, N and S, C₆₋₁₀ aryl, or 5- or 6-membered heteroaryl comprising 1-3 heteroatoms selected from O, N and S, where alkyl is optionally substituted with 1 to 3 R⁸ and where cycloalkyl, heterocycloalkyl, aryl and heteroaryl are optionally substituted with 1 to 4 R¹¹; or R⁷ and R⁷ together with the nitrogen atom to which they are attached form a 4 to 7 membered heterocycloalkyl ring optionally comprising 1 to 2 additional heteroatoms selected from O, N and S, optionally substituted with 1 to 4 R⁹; or R² and R⁷ together with the nitrogen atoms to which they are attached form a 6- or 7-membered heterocycloalkyl ring; or R³ and R⁷ together with the nitrogen and carbon atoms to which they are attached form a 5- or 6-membered heterocycloalkyl ring optionally comprising 1 to 2 additional heteroatoms selected from O, N and S, optionally substituted with 1 to 4 substituents each one independently selected from C₁₋₆ alkyl, C₁₋₆ haloalkyl, halogen, -OH, CN, and -NH₂; each R⁸ is -C(O)OH, C₃₋₇ cycloalkyl, a 4 to 7 membered heterocycloalkyl ring comprising 1-3 heteroatoms selected from O, N and S, C₆₋₁₀ aryl, or 5 or 6 membered heteroaryl comprising comprises 1-3 heteroatoms selected from O, N and S, wherein cycloalkyl, heterocycloalkyl, aryl and heteroaryl are optionally substituted with 1 to 4 R¹⁰; each R⁹ is independently at each occurrence C₁₋₆ alkyl, C₁₋₆ alkoxy, C₁₋₆ haloalkyl, C₁₋₆ haloalkoxy, halogen, -OH, CN, -NR¹²R¹³, or -NH₂, where the alkoxy is optionally substituted with 1 to 3 substituents independently selected from C₃₋₇ cycloalkyl, a 4- to 7-membered heterocycloalkyl ring comprising 1-3 heteroatoms selected from O, N, and S, C₆₋₁₀ aryl, and 5- or 6-membered heteroaryl comprising 1-3 heteroatoms selected from O, N and S; or two R⁹ together with the atoms to which they are attached form a C₅₋₇ cycloalkyl or a 5 to 7 membered heterocycloalkyl ring comprising 1-2 heteroatoms selected from O, N and S; each R¹⁰ is independently at each occurrence C₁₋₆ alkyl, C₁₋₆ haloalkyl, C₁₋₆ alkoxy, C₁₋₆ haloalkoxy, halogen, -OH, CN, O -NH₂; or two R¹⁰ together with the atoms to which they are attached form a C₄₋₇ cycloalkyl or a 5 to 7 membered heterocycloalkyl ring comprising 1-2 heteroatoms selected from O, N and S optionally substituted with one or more C₁₋₆ alkyl , C₁₋₆ haloalkyl, halogen, -OH, CN, or -NH₂; each R¹¹ is independently at each occurrence C₁₋₆ alkyl, C₁₋₆ haloalkyl, C₁₋₆ alkoxy, C₁₋₆ haloalkoxy, halogen, -OH, CN, or -NH₂; R¹² and R¹³ are each independently selected from C₁₋₆ alkyl, C₁₋₆ haloalkyl, C₃₋₇ cycloalkyl, a 4 to 7 membered heterocycloalkyl ring comprising 1-3 heteroatoms selected from O, N and S, C₆₋₁₀ aryl , and 5- or 6-membered heteroaryl comprising 1-3 heteroatoms selected from O, N and S; m and m1 are each independently 0, 1, or 2; n1 is 0, 1, 2, or 3; n2 and n3 are each independently 1 or 2; and each s and n is independently 1, 2, or 3, where s + n is £4; or pharmaceutically acceptable salts, hydrates, solvates, prodrugs, stereoisomers, and tautomers thereof. |
| priorityDate | 2018-07-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 21.